ClinConnect ClinConnect Logo
Search / Trial NCT07107919

Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective

Launched by THE AFFILIATED HOSPITAL OF QINGDAO UNIVERSITY · Jul 31, 2025

Trial Information

Current as of August 19, 2025

Recruiting

Keywords

Ckd Cardiac Magnetic Resonance 18 F Fapi

ClinConnect Summary

This clinical trial is studying how chronic kidney disease (CKD) affects the heart by using a special type of imaging called 18F-FAPI PET/MR. This imaging helps doctors see how well the heart is working and if there is any scarring in the heart muscle. The study includes people with different stages of CKD—from mild to more advanced kidney problems—to understand how kidney health and heart health are connected.

If you are between 18 and 80 years old and have been diagnosed with chronic kidney disease, you might be eligible to join this study. You will need to give written permission to participate and agree to the imaging tests, which are safe but require lying still inside a machine for a short time. Women who can have children and men will also need to use effective birth control during the study and for six months afterward. The study does not include people who are pregnant, have serious heart or other health problems, or cannot safely undergo the imaging tests. By participating, you will help researchers learn more about how kidney disease affects the heart, which could improve future care for people with CKD.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age between 18 and 80 years, regardless of sex.
  • 2. Clinically diagnosed with chronic kidney disease (CKD), based on KDIGO guidelines.
  • 3. Complete clinical data available.
  • 4. Written informed consent for participation and for undergoing 18F-FAPI PET/MR imaging is obtained from the patient or their legal guardian.
  • 5. Female participants must agree to use effective contraception during the study and for at least 6 months after its completion (e.g., sterilization, intrauterine hormonal devices, condoms, hormonal contraceptives, abstinence, or vasectomized partner). Male participants must also agree to use contraception during the study and for 6 months after its completion.
  • Exclusion Criteria:
  • 1. Women who are planning to conceive, currently pregnant, or breastfeeding.
  • 2. Contraindications to PET/MR imaging, including but not limited to metal implants, claustrophobia, or inability to tolerate cardiac MRI due to respiratory difficulties.
  • 3. History of allergy or hypersensitivity to gadolinium-based contrast agents.
  • 4. Presence of malignant tumors or other serious progressive diseases.
  • 5. Patients with severe cardiac conditions, such as advanced heart failure, severe valvular disease, or cardiomyopathies.
  • 6. Hemodynamic instability.
  • 7. Presence of severe systemic or localized infections, or other serious comorbid conditions.
  • 8. Incomplete clinical data.
  • 9. Any other reason deemed by the investigators to make the subject unsuitable for participation, including inability or unwillingness to comply with study procedures and requirements.
  • 10. Determined by the investigators to be inappropriate for inclusion in the study.

About The Affiliated Hospital Of Qingdao University

The Affiliated Hospital of Qingdao University is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive expertise in various medical disciplines to enhance patient care and contribute to the global medical community. With a strong focus on translational medicine, the Affiliated Hospital collaborates with academic and industry partners to facilitate the development of novel therapies and medical interventions, ensuring adherence to the highest ethical standards and regulatory guidelines. Through its commitment to excellence in research and patient outcomes, the hospital aims to drive significant advancements in medical science and improve the quality of life for patients.

Locations

Qingdao, Shandong, China

Patients applied

0 patients applied

Trial Officials

Pei Nie

Principal Investigator

The Affiliated Hospital of Qingdao University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported